Miscellaneous Hormones

Sun, 2014, Calcitonin nasal spray and increased cancer risk: a population-based nested case-control study, J Clin Endocrinol Metab, 99, 4259, 10.1210/jc.2014-2239 Overman, 2013, Salmon calcitonin use and associated cancer risk, Ann Pharmacother, 47, 1675, 10.1177/1060028013509233 Shore, 2013, Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer, Urol Nurs, 33, 236, 10.7257/1053-816X.2013.33.5.236 Lee, 2014, Is high-dose leuprorelin acetate effective and safe in Asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial, Yonsei Med J, 55, 310, 10.3349/ymj.2014.55.2.310 Gandaglia, 2014, Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer, Eur Urol, 66, 1125, 10.1016/j.eururo.2014.01.026 Taplin, 2014, Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study, J Clin Oncol, 32, 3705, 10.1200/JCO.2013.53.4578 Jespersen, 2014, Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study, Eur Urol, 65, 704, 10.1016/j.eururo.2013.02.002 Koo, 2013, Treatment outcomes of chemical castration on Korean sex offenders, J Forensic Legal Med, 20, 563, 10.1016/j.jflm.2013.06.003 Song, 2013, Clinical study on the effectiveness and safety of combined laparoscopy and gonadotropin-releasing hormone agonist in the treatment of endometriosis, Zhonghua Fu Chan Ke Za Zhi, 48, 584 Hammar, 2013, Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization, BMC Pregnancy Childbirth, 13, 201, 10.1186/1471-2393-13-201 Lee, 2014, Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty, Ann Pediatr Endocrinol Metab, 19, 135, 10.6065/apem.2014.19.3.135 Lee, 2014, 36-Month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty, J Clin Endocrinol Metab, 99, 3153, 10.1210/jc.2013-4471 Davis, 2014, Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty, J Pediatr Surg, 49, 807, 10.1016/j.jpedsurg.2014.02.067 Mamidala, 2013, Maternal hormonal interventions as a risk factor for Autism Spectrum Disorder: an epidemiological assessment from India, J Biosci, 38, 887, 10.1007/s12038-013-9376-x Kamath, 2014, Use of GnRH analogues pre-operatively for hysteroscopic resection of submucous fibroids: a systematic review and meta-analysis, Eur J Obstet Gynecol Reprod Biol, 177, 11, 10.1016/j.ejogrb.2014.03.009 Saggar, 2013, Alopecia with endocrine therapies in patients with cancer, Oncologist, 18, 1126, 10.1634/theoncologist.2013-0193 Walker, 2013, Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects, Clin Genitourin Cancer, 11, 375, 10.1016/j.clgc.2013.05.004 Calcaterra, 2013, Hypertension during therapy with triptorelin in a girl with precocious puberty, Indian J Pediatr, 80, 884, 10.1007/s12098-012-0898-2 Huang, 2013, Pituitary apoplexy induced by gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case, World J Surg Oncol, 11, 254, 10.1186/1477-7819-11-254 Burris, 2014, Leuprolide acetate-induced generalized papular eruption, J Drugs Dermatol, 13, 755 Tashiro, 2014, Giant subcutaneous hematoma with hemorrhagic shock induced by goserelin acetate injection for prostate cancer: report of a case, Hinyokika Kiyo, 60, 455 Fatemi, 2014, Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol, Fertil Steril, 101, 1008, 10.1016/j.fertnstert.2014.01.019 Patterson, 2014, Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study, J Clin Endocrinol Metab, 99, 2030, 10.1210/jc.2013-4159 Tritos, 2014, Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis, J Clin Endocrinol Metab, 99, 2018, 10.1210/jc.2014-1013 Linglart, 2015, Growth hormone treatment for childhood short stature and risk of stroke in early adulthood, Neurology, 84, 1062, 10.1212/WNL.0000000000001385 Rasmussen, 2014, A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile, J Clin Endocrinol Metab, 99, E1819, 10.1210/jc.2014-1702 Biller, 2013, 12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency, Pituitary, 16, 311, 10.1007/s11102-012-0422-8 Kirschner, 2014, Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study, Neuromuscul Disord, 24, 134, 10.1016/j.nmd.2013.10.011 Kappelgaard, 2014, The impact of long-term growth hormone treatment on metabolic parameters in Japanese patients with short stature born small for gestational age, Horm Res Paediatr, 81, 272, 10.1159/000358196 Ciresi, 2014, Corneal thickness in children with growth hormone deficiency: the effect of GH treatment, Growth Horm IGF Res, 24, 150, 10.1016/j.ghir.2014.05.001 Kim, 2014, Efficacy of short-term growth hormone treatment in prepubertal children with idiopathic short stature, Yonsei Med J, 55, 53, 10.3349/ymj.2014.55.1.53 Khadilkar, 2014, 24-Month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency, J Clin Endocrinol Metab, 99, 126, 10.1210/jc.2013-2502 Mostoufi-Moab, 2013, Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy, Pediatr Blood Cancer, 60, 1766, 10.1002/pbc.24667 Simon, 2013, Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study, J Clin Endocrinol Metab, 98, 2746, 10.1210/jc.2012-4201 Loche, 2014, Growth hormone treatment in non-growth hormone-deficient children, Ann Pediatr Endocrinol Metab, 19, 1, 10.6065/apem.2014.19.1.1 van Bunderen, 2014, Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity, Clin Endocrinol, 81, 1, 10.1111/cen.12477 Appelman-Dijkstra, 2013, Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review, Eur J Endocrinol, 169, R1, 10.1530/EJE-12-1088 Breederveld, 2014, Recombinant human growth hormone for treating burns and donor sites, Cochrane Database Syst Rev, 9, CD008990 Naftel, 2013, Progression of Chiari I malformations while on growth hormone replacement: a report of two cases, Childs Nerv Syst, 29, 2291, 10.1007/s00381-013-2080-1 Uihlein, 2014, Growth hormone replacement in patients with PHACE association and hypopituitarism, Pediatr Dermatol, 31, 337, 10.1111/pde.12306 Neggers, 2014, Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly, J Clin Endocrinol Metab, 99, 3644, 10.1210/jc.2014-2032 Jen, 2013, Pegvisomant bioavailability of single 30mg/mL subcutaneous injection compared to two 15mg/mL subcutaneous injections: a pharmacokinetic, safety and tolerability study, Growth Hormon IGF Res, 23, 114, 10.1016/j.ghir.2013.04.002 Jacob, 2014, Type 1 drug hypersensitivity following first dose of pegvisomant, Clin Endocrinol, 80, 315, 10.1111/cen.12230 Galley, 2014, Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis, J Pineal Res, 56, 427, 10.1111/jpi.12134 Wade, 2014, Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial, Clin Interv Aging, 9, 947 Hansen, 2014, Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial, Breast Cancer Res Treat, 145, 683, 10.1007/s10549-014-2962-2 Pokharel, 2014, Premedication with oral alprazolam and melatonin combination: a comparison with either alone—a randomized controlled factorial trial, Biomed Res Int, 2014, 356964, 10.1155/2014/356964 Khezri, 2013, Effect of melatonin and gabapentin on anxiety and pain associated with retrobulbar eye block for cataract surgery: a randomized double-blind study, Indian J Pharmacol, 45, 581, 10.4103/0253-7613.121368 Fallah, 2015, Safety and efficacy of melatonin in pediatric migraine prophylaxis, Curr Drug Saf, 10, 132, 10.2174/1574886309666140605114614 Mostafavi, 2014, Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial, Acta Med Iran, 52, 734 Bruni, 2015, Current role of melatonin in pediatric neurology: clinical recommendations, Eur J Paediatr Neurol, 19, 122, 10.1016/j.ejpn.2014.12.007 Friedman, 2014, Pharmacological treatments of non-substance-withdrawal delirium: a systematic review of prospective trials, Am J Psychiatry, 171, 151, 10.1176/appi.ajp.2013.13040458 Whitehouse, 2013, Complementary and alternative medicine for autism spectrum disorders: rationale, safety and efficacy, J Paediatr Child Health, 49, E438, 10.1111/jpc.12242 McCleery, 2014, Pharmacotherapies for sleep disturbances in Alzheimer's disease, Cochrane Database Syst Rev, 3, CD009178 Singer, 2003, A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease, Sleep, 26, 893, 10.1093/sleep/26.7.893 Kuriyama, 2014, Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis, Sleep Med, 15, 385, 10.1016/j.sleep.2013.11.788 Mukta, 2013, Role of misoprostol 600 mcg oral in active management of third stage of labor: a comparative study with oxytocin 10IU i.m, J Obstet Gynaecol India, 63, 325, 10.1007/s13224-012-0330-x Chaudhuri, 2014, Rectally administrated misoprostol as an alternative to intravenous oxytocin infusion for preventing post-partum hemorrhage after cesarean delivery, J Obstet Gynaecol Res, 40, 2023, 10.1111/jog.12464 Tewatia, 2014, Sublingual misoprostol versus intravenous oxytocin in prevention of post-partum hemorrhage, Arch Gynecol Obstet, 289, 739, 10.1007/s00404-013-3026-2 Elgafor el Sharkwy, 2013, Carbetocin versus sublingual misoprostol plus oxytocin infusion for prevention of postpartum hemorrhage at cesarean section in patients with risk factors: a randomized, open trail study, Arch Gynecol Obstet, 288, 1231, 10.1007/s00404-013-2896-7 Wiberg-Itzel, 2014, Level of lactate in amniotic fluid and its relation to the use of oxytocin and adverse neonatal outcome, Acta Obstet Gynecol Scand, 93, 80, 10.1111/aogs.12261 Morikawa, 2014, Do uterotonic drugs increase risk of abruptio placentae and eclampsia?, Arch Gynecol Obstet, 289, 987, 10.1007/s00404-013-3101-8 Rosseland, 2013, Changes in blood pressure and cardiac output during cesarean delivery: the effects of oxytocin and carbetocin compared with placebo, Anesthesiology, 119, 541, 10.1097/ALN.0b013e31829416dd Bruyere, 2014, QT interval prolongation following carbetocin in prevention of post-cesarean delivery hemorrhage, Int J Obstet Anesth, 23, 88, 10.1016/j.ijoa.2013.05.003 Heuser, 2013, Tachysystole in term labor: incidence, risk factors, outcomes, and effect on fetal heart tracings, Am J Obstet Gynecol, 209, 10.1016/j.ajog.2013.04.004 Mameli, 2014, Oxytocin nasal spray in fibromyalgic patients, Rheumatol Int, 34, 1047, 10.1007/s00296-014-2953-y Khan, 2014, Carbetocin at elective Cesarean delivery: a sequential allocation trial to determine the minimum effective dose, Can J Anaesth, 61, 242, 10.1007/s12630-013-0082-9 Anandakrishnan, 2013, Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose, part 2, Can J Anaesth, 60, 1054, 10.1007/s12630-013-0028-2 Gizzo, 2013, Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: a systematic review, Reprod Sci, 20, 1011, 10.1177/1933719112468951 Vlachos, 2014, Oxytocin discontinuation after the active phase of labor is established, J Matern Fetal Neonatal Med, 18, 1 Budden, 2014, High-dose versus low-dose oxytocin infusion regimens for induction of labour at term, Cochrane Database Syst Rev, 10, CD009701 Kenyon, 2013, High-dose versus low-dose oxytocin for augmentation of delayed labour, Cochrane Database Syst Rev, 7, CD007201 Preti, 2014, Oxytocin and autism: a systematic review of randomized controlled trials, J Child Adolesc Psychopharmacol, 24, 54, 10.1089/cap.2013.0040 Nandhakumar, 2013, Acute hypoxemia in a parturient with primary ciliary dyskinesia following the administration of intravenous oxytocin: a case report, Can J Anaesth, 60, 1218, 10.1007/s12630-013-0039-z Minowa, 2013, A case of myocardial ischemia inducedby oxytocin during cesarean section, Masui, 62, 982 Liu, 2014, Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects, Clin Ther, 36, 940, 10.1016/j.clinthera.2014.03.015 Fujita, 2014, Once-weekly injection of low-dose teriparatide (28.2 mug) reduced the risk of vertebral fracture in patients with primary osteoporosis, Calcif Tissue Int, 94, 170, 10.1007/s00223-013-9777-8 Tsai, 2013, Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial, Lancet, 382, 50, 10.1016/S0140-6736(13)60856-9 Walker, 2013, Combination therapy with risedronate and teriparatide in male osteoporosis, Endocrine, 44, 237, 10.1007/s12020-012-9819-4 Dominguez, 2014, Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide, J Am Acad Dermatol, 70, e41, 10.1016/j.jaad.2013.10.013 Delivanis, 2013, Subungual exostosis in an osteoporotic patient treated with teriparatide, Endocr Pract, 19, e115, 10.4158/EP13040.CR Caplin, 2014, Lanreotide in metastatic enteropancreatic neuroendocrine tumors, N Engl J Med, 371, 1556 Temmerman, 2013, Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data, Aliment Pharmacol Ther, 38, 397, 10.1111/apt.12384 Martin-Richard, 2013, Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study, BMC Cancer, 13, 427, 10.1186/1471-2407-13-427 Myint, 2014, Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials, Nephrology, 19, 217, 10.1111/nep.12211 Jayakrishnan, 2014, Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis, Ann Surg Oncol, 21, 240, 10.1245/s10434-013-3300-3 Chieffo, 2013, Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly, J Clin Endocrinol Metab, 98, 4047, 10.1210/jc.2013-2262 Fukuhara, 2015, Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma, Endocr J, 62, 21, 10.1507/endocrj.EJ14-0118 Nardone, 2014, Long acting release-octreotide as “rescue” therapy to control angiodysplasia bleeding: a retrospective study of 98 cases, Dig Liver Dis, 46, 688, 10.1016/j.dld.2014.04.011 Caroli, 2013, Effect of long acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial, Lancet, 382, 1485, 10.1016/S0140-6736(13)61407-5 Hoff, 2014, Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial, J Clin Oncol, 32, 1006, 10.1200/JCO.2013.50.8077 van Hulsteijn, 2013, Effects of octreotide therapy in progressive head and neck paragangliomas: case series, Head Neck, 35, E391, 10.1002/hed.23348 Chen, 2014, Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study, Clin Ther, 36, 1196, 10.1016/j.clinthera.2014.06.006 Breitschaft, 2014, Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study, Diabetes Res Clin Pract, 103, 458, 10.1016/j.diabres.2013.12.011 Petersenn, 2014, Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study, Pituitary, 17, 132, 10.1007/s11102-013-0478-0 Pivonello, 2014, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study, Clin Endocrinol, 81, 408, 10.1111/cen.12431 Shenouda, 2014, An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels, Am J Ther, 21, 164, 10.1097/MJT.0b013e31824c3eb4 Henry, 2013, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers, J Clin Endocrinol Metab, 98, 3446, 10.1210/jc.2013-1771 Deloose, 2014, A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome, Neurogastroenterol Motil, 26, 803, 10.1111/nmo.12333 Allen, 2014, Pasireotide for postoperative pancreatic fistula, N Engl J Med, 371, 875, 10.1056/NEJMc1407470 Kinugawa, 2014, Efficacy and safety of tolvaptan in heart failure patients with volume overload, Circ J, 78, 844, 10.1253/circj.CJ-14-0126 Patra, 2014, Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India, Heart Views, 15, 1, 10.4103/1995-705X.132136 Nistor, 2015, Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials, Int Urol Nephrol, 47, 335, 10.1007/s11255-014-0855-2 Kalra, 2014, Vasopressin receptor antagonists: from pivotal trials to current practice, Curr Heart Fail Rep, 11, 10, 10.1007/s11897-013-0175-3 Ahmed, 2015, The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia, World J Urol, 33, 649, 10.1007/s00345-014-1378-2 Goldberg, 2014, Low-dose oral desmopressin for treatment of nocturia and nocturnal enuresis in patients after radical cystectomy and orthotopic urinary diversion, BJU Int, 114, 727, 10.1111/bju.12598 Weiss, 2013, Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study, J Urol, 190, 965, 10.1016/j.juro.2012.12.112 Sharma, 2014, Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeries, J Pediatr Hematol Oncol, 36, e371, 10.1097/MPH.0000000000000185 Ray, 2014, Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders, Cochrane Database Syst Rev, 11, CD010338 Ebell, 2014, A systematic review of the efficacy and safety of desmopressin for nocturia in adults, J Urol, 192, 829, 10.1016/j.juro.2014.03.095 Zachoval, 2013, Nocturnal polyuria, treatment with desmopressin, Ceska Gynekol, 78, 385 Lucchini, 2013, Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review, J Pediatr Urol, 9, 1049, 10.1016/j.jpurol.2013.02.012 Cetinel, 2013, Management of lower urinary tract dysfunction in multiple sclerosis: a systematic review and Turkish consensus report, Neurourol Urodyn, 32, 1047, 10.1002/nau.22374 Shah, 2014, In-stent thrombosis following DDAVP administration: case report and review of the literature, Blood Coagul Fibrinolysis, 25, 81, 10.1097/MBC.0b013e328364c232 Bhaskar, 2014, Polyuria after cessation of vasopressin in a child after cardiac surgery, J Cardiothorac Vasc Anesth, 28, e24, 10.1053/j.jvca.2014.01.014 Ghosh, 2013, Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study, Liver Int, 33, 1187, 10.1111/liv.12179 Wan, 2014, A comparative study of high-or low-dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome, Zhonghua Gan Zang Bing Za Zhi, 22, 349 Sidhu, 2013, Terlipressin-induced QT prolongation, Intern Med J, 43, 1050, 10.1111/imj.12222 Kim, 2013, Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome, Clin Mol Hepatol, 19, 417, 10.3350/cmh.2013.19.4.417 Wang, 2013, Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient, Kaohsiung J Med Sci, 29, 691, 10.1016/j.kjms.2013.08.003 Zaki, 2013, Terlipressin-induced hyponatremic seizure in a child, Indian J Pharmacol, 45, 403, 10.4103/0253-7613.114995 Ozel Coskun, 2014, Terlipressin-induced ischemic skin necrosis: a rare association, Am J Case Rep, 15, 476, 10.12659/AJCR.891084 Cho, 2013, Under general anesthesia arginine vasopressin prevents hypotension but impairs cerebral oxygenation during arthroscopic shoulder surgery in the beach chair position, Anesth Analg, 117, 1436, 10.1213/ANE.0b013e3182a8fa97 Van Haren, 2013, Vasopressin for cerebral perfusion pressure management in patients with severe traumatic brain injury: preliminary results of a randomized controlled trial, J Trauma Acute Care Surg, 75, 1024, 10.1097/TA.0b013e3182a99d48 Acker, 2014, Vasopressin improves hemodynamic status in infants with congenital diaphragmatic hernia, J Pediatr, 165, 10.1016/j.jpeds.2014.03.059